Jazz Pharmaceuticals
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Jazz Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#212 of 15,742 sponsors by registered trial count).
Jazz Pharmaceuticals: 128 sponsored US clinical trials, 15 recruiting.
Jazz Pharmaceuticals sponsors 128 registered US clinical trials on ClinicalTrials.gov, 15 of them currently recruiting, and 81 completed. 50 of these trials are in Phase 3-4 (later-stage) and 69 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Narcolepsy, with 5 trials.
Top-decile sponsor footprint
Jazz Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#212 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
81 of 108 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (75.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
128 total, page 1 of 3
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy Participants
NCT07377539
Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma
NCT07282587
A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures
NCT07233239
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
NCT07102381
Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy
NCT06113237
A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1
NCT06961266
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
NCT06695845
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
NCT06435429
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
NCT06282575
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
NCT06108050
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
NCT05734066
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
NCT05580562
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
NCT05557045
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
NCT04541082
Child and Adolescent Registry for Participants With Narcolepsy
NCT04899947
A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex
NCT05864846
Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
NCT05044819
A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH
NCT07625280
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
NCT07459634
A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma
NCT07533942
A Study to Investigate the Effect of XYWAV on Sleepiness, Polysomnography, and Functional Outcomes in Participants With Idiopathic Hypersomnia or Narcolepsy
NCT05875974
A Switch Study From High-Sodium Oxybate to XYWAV to Evaluate Changes in Blood Pressure in Participants With Narcolepsy
NCT05869773
A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JZP441 in Healthy Participants
NCT05720494
A JZP341 Study in Adult Participants With Advanced or Metastatic Solid Tumors
NCT05631327
A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease
NCT05642442
A Study to Investigate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP441 in Sleep-deprived Healthy Participants
NCT05651152
Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures
NCT05288283
Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors
NCT05126433
A Study of JZP150 in Adults With Posttraumatic Stress Disorder
NCT05178316
A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)
NCT05122650
A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer
NCT05027139
Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis
NCT04984278
To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)
NCT04894591
Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder
NCT04745026
Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures
NCT04485104
Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia
NCT04571645
A Patient-Centric, Prospective, Observational, Non-Interventional Switch Study of XYWAV in Narcolepsy
NCT04803786
An Interventional Safety Switch Study (Segue Study) of XYWAV in Narcolepsy
NCT04794491
A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers
NCT04466891
Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis
NCT04203498
Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment
NCT04421456
Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure
NCT04389840
A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer
NCT04224272
A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome
NCT04252586
Safety and Tolerability of Cannabidivarin (CBDV) in Children and Young Adults With Autism Spectrum Disorder
NCT03849456
An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)
NCT04145531
A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia
NCT04075747
A Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line Treatment for Subjects With AML
NCT04038437
A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity
NCT03954106
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
NCT03929666
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 26 |
| Phase 2 | 43 |
| Phase 3 | 44 |
| Phase 4 | 6 |
Therapeutic Areas
What is open in the Jazz Pharmaceuticals pipeline
15 recruiting of 128 indexed (12% open); 81 completed (63%).
Phase mix: 50 late (III/IV) vs 69 early (I/II) (balanced across stages).
Top condition: Narcolepsy (5 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Jazz Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 128 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
Jazz Pharmaceuticals sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 128 trials (± recruiting share)
- University of Illinois at Urbana-Champaign · 129 trials · 14% recruiting
- Stony Brook University · 127 trials · 19% recruiting
- Rhode Island Hospital · 130 trials · 20% recruiting
- The Methodist Hospital Research Institute · 126 trials · 39% recruiting
Sponsors near 12% open enrollment (± trial volume)
- Cochlear · 12% recruiting · 34 trials
- Erchonia Corporation · 12% recruiting · 34 trials
- Hutchmed · 12% recruiting · 17 trials
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group · 12% recruiting · 17 trials
Related
What to do with this Jazz Pharmaceuticals page
128 registered trials is a research-attention snapshot, not an endorsement of Jazz Pharmaceuticals or any single study.
- 15 of Jazz Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Narcolepsy is the condition Jazz Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Narcolepsy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Jazz Pharmaceuticals pipeline card: 128 registered trials from official public datasets.Report a data error.